ScreenerHero

INVAInnoviva, Inc.

NAS · US · Healthcare · Biotechnology · inva.com
21.07USD-1.91%Mkt Cap: 1.52B $P/E: 4.88

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.52B $
Enterprise Value1.27B $
Revenue (TTM)440.00M $
Gross Profit333.94M $
Net Income (TTM)271.17M $
Revenue/Share6.036 USD
Last Price21.07 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees159
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS45781M1018
Valuation
P/E (Trailing)4.88
P/E (Forward)9.50
PEG0.31
EV/EBITDA6.50
EV/Revenue2.88
P/S3.45
P/B1.24
EPS (TTM)4.22
EPS (Forward)2.21
52W Range
16.5253% of range25.15
52W High25.15 USD
52W Low16.52 USD
Profitability
Gross Margin81.19%
Oper. Margin43.28%
EBITDA Margin44.41%
Profit Margin65.92%
ROE23.12%
ROA16.58%
Growth
Revenue Growth19.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF196.93M $
CapEx (TTM)10.50M $
FCF Margin25.08%
FCF Yield7.25%
Net Debt-247.82M $
Net Debt/EBITDA-1.27
Balance Sheet
Debt/Equity0.23
Current Ratio16.01
Quick Ratio14.65
Book Value/Sh16.98 USD
Cash/Share8.015 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateSep 8, 2015
Pay DateSep 30, 2015
Splits
Last Split1241:1000
Split DateJun 3, 2014
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.00 USD
Upside (mean)+66.1%
Target Range18.00 USD – 46.00 USD
$18.00+66.1% to mean$46.00
# Analysts4
Ownership
Shares Out.72.25M
Float67.65M
Insiders1.01%
Institutions109.50%
Short Interest
Short Ratio9.2d
Short % Float12.95%
Short % Out.9.54%
Shares Short6.89M
Short (prev mo.)6.65M
Technical
SMA 5021.85 (-3.6%)
SMA 20021.75 (-3.1%)
Beta0.34
S&P 52W Chg18.16%
Avg Vol (30d)642.73K
Avg Vol (10d)673.76K
Technical Indicators
RSI (14)47.4
MACD-0.2137
MACD Signal-0.3036
MACD Hist.+0.0899
BB Upper21.78 USD
BB Middle21.05 USD
BB Lower20.33 USD
BB Width6.87%
ATR (14)0.5690 USD
Vol Ratio (20d)0.74x